Antimicrobial

SCYNEXIS to Present Positive Interim Data from the Phase 3 FURI Study of Oral Ibrexafungerp at IDWeek 2022

JERSEY CITY, N.J., Oct. 11, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to…

2 years ago

Oyster Point Pharma to Present New Scientific Analyses at World Cornea Congress VIII

Two Featured Presentations will Include a Post-Hoc Analysis of TYRVAYA® (varenicline solution) Nasal Spray and Tear Film Cytokine ResearchPRINCETON, N.J.,…

2 years ago

Paratek Pharmaceuticals to Host Investor Update on the Global Opportunity in Non-Tuberculous Mycobacteria (NTM)

Oct. 3 Webinar Features Presentations by Scientific Leaders in NTM and Paratek’s Management TeamBOSTON, Sept. 26, 2022 (GLOBE NEWSWIRE) --…

2 years ago

BioLife Sciences Inc. (OTC: BLFE) Enters Into Negotiations for Exclusive Licensing Deal With Canadian Firm

HENDERSON, NV, Sept. 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioLife Sciences (OTCPK: BLFE) is pleased to announce that…

2 years ago

LumiraDx Partners with British In Vitro Diagnostics Association to Report on the Role of Rapid Diagnostics in Tackling Antimicrobial Resistance

Testing Times Report reflects expert opinion that “Supporting more widespread use of rapid diagnostic technology should be a central aim…

2 years ago

GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr

The exclusive license allows GSK to commercialize tebipenem HBr in all territories, except Japan and certain other Asian countries Spero…

2 years ago

OpGen Subsidiary Curetis and FIND Sign R&D Collaboration Agreement for Unyvero A30 RQ Platform

FIND, the global alliance for diagnostics, together with German KfW bank co-funds development of Unyvero A30 RQ platform for low…

2 years ago

AXIM® Biotechnologies Signs Exclusive Global Commercialization Agreement With Verséa™ Ophthalmics for Distribution and Sales of Novel Ophthalmic Diagnostics Solutions

Under the Agreement the Company will Sell and Distribute Globally AXIM’s Readers and Three Novel Proprietary Tests Designed for Diagnosis…

2 years ago